Watanabe Guy, Horita Shoichiro, Moriya Reika Flora, Masuishi Yusuke, Misaka Shingen, Taira Shu, Shimomura Kenju, Shimabukuro Michio, Kazama Junichiro James
Department of Nephrology and Hypertension, Fukushima Medical University School of Medicine, Fukushima, Japan.
Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Physiol Rep. 2025 Apr;13(7):e70320. doi: 10.14814/phy2.70320.
Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has direct renoprotective effects beyond lowering blood glucose levels. The inhibition of sodium reabsorption via SGLT2 reduces the overload on proximal tubules, thereby suppressing the generation of reactive oxygen species (ROS) and preventing a decline in renal function. To clarify the pharmacological mechanism of SGLT2 inhibitor, we investigated the effects of canagliflozin on oxidative stress in the kidneys of normal, non-diabetic Sprague-Dawley rats. Screening using mass spectrometry images revealed a significant elevation map of the reduced form of glutathione in the renal cortex of canagliflozin-treated non-diabetic rats. These results suggest that canagliflozin reduces oxidative stress through ROS scavenging mechanisms. Considering that ROS play major roles in renal dysfunction regardless of diabetes mellitus, these findings suggest that canagliflozin is applicable to a broader range of renal diseases beyond diabetes.
卡格列净是一种钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,除了降低血糖水平外,还具有直接的肾脏保护作用。通过SGLT2抑制钠重吸收可减轻近端小管的负荷,从而抑制活性氧(ROS)的产生并防止肾功能下降。为阐明SGLT2抑制剂的药理机制,我们研究了卡格列净对正常、非糖尿病的Sprague-Dawley大鼠肾脏氧化应激的影响。使用质谱成像进行筛选发现,在接受卡格列净治疗的非糖尿病大鼠的肾皮质中,谷胱甘肽还原形式的图谱显著升高。这些结果表明,卡格列净通过ROS清除机制减轻氧化应激。鉴于无论是否患有糖尿病,ROS在肾功能障碍中都起主要作用,这些发现表明卡格列净适用于糖尿病以外更广泛的肾脏疾病。